The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.
The research involved 14,358 individuals enrolled in the federally funded Childhood Cancer Survivor Study (CCSS). St. Jude Children's Research Hospital investigators leading the effort reported that 1,382, or 9.6 percent, of survivors developed new tumors unrelated to their original cancers. About 30 percent of those survivors, 386 individuals, developed third tumors. Four or more tumors were found in 153 survivors in this study. The results appear in the June 27 online edition of the Journal of Clinical Oncology.
"These findings show that when you describe adult survivors of childhood cancer it is not sufficient to describe their risk of a first subsequent cancer, but to acknowledge that some of these patients are at risk for multiple cancers. This is the first study to more fully enumerate that risk," said Gregory Armstrong, M.D., the study's principal investigator and an assistant member of the St. Jude Department of Epidemiology and Cancer Control.
The work underscores the importance of cancer screenings for this growing population. "Too often, survivors still are not getting these important cancer screening tests beginning as early or as often as recommended," Armstrong said. For example, mammograms beginning at age 25 rather than age 40 are recommended for female survivors whose childhood treatment included chest radiation of 20 grays or more. A gray is a measure of absorbed radiation.
An estimated 366,000 Americans alive today are childhood cancer survivors. With overall long-term childhood cancer survival rates now at 80 percent, the ranks of survivors are expected to keep growing. The CCSS was launched in 1994 to identify the challenges facing childhood cancer survivors and to develop new methods to ease or prevent late effects. St. Jude is the study's central coordinating institution. St. Jude scientists are also focused on using genomics and other tools to develop the next generation of cancer therapies and better match patients with existing therapy to increase cures but decrease the risk of treatment-related toxicities, including second cancers.
In this study, half of the participants had survived at least 23 years since their childhood cancers were found. Their median age was 32 years old, meaning most had yet to reach the age when rates of prostate, breast and other cancers increase sharply in the general population.
Almost 70 percent of study participants received radiation as part of their successful childhood cancer treatment. This study reinforced earlier research that linked radiation therapy with an increased risk of developing additional tumors, malignant and benign, later in life. Female survivors whose childhood cancer treatment included radiation were among those at highest risk for later tumors, particularly breast tumors.
For 735 survivors, the second tumors were malignant and thus life-threatening.
Risks were also associated with benign tumors. Investigators showed survivors whose second tumor was a non-melanoma skin cancer had a 1 in 5 chance of being diagnosed with another, more aggressive cancer within 15 years. The group included 485 survivors with either basal or squamous cell skin cancers. "These survivors are candidates for additional genetic evaluation to look for an underlying genetic propensity for tumor development or an inability to protect healthy cells against the harmful effects of radiation," Armstrong said.
Of the 176 survivors whose second tumors were found in the breast, 42 women developed multiple tumors. For many, researchers reported that the tumors apparently developed independently in both breasts almost simultaneously. "This finding reinforces previous reports of multiple breast cancers and defines them as a significant risk," Armstrong said.
This study included survivors whose cancers were found between 1970 and 1986 when they were age 20 or younger. Participants were treated at one of 26 institutions in the United States or Canada and survived at least five years after their cancer diagnosis.
The other authors were Wei Liu, Deokuma Srivastava and senior author Les Robison, all of St. Jude; Wendy Leisenring, Fred Hutchison Cancer Research Center; Yutaka Yasui, University of Alberta; Sue Hammond, The Ohio State University; Smita Bhatia, City of Hope; Joseph Neglia, University of Minnesota Medical School; and Marilyn Stovall, University of Texas MD Anderson Cancer Center.
The National Cancer Institute and ALSAC funded this research.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked one of the best pediatric cancer hospitals in the country, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has treated children from all 50 states and from around the world, serving as a trusted resource for physicians and researchers. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.
Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,700 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital's work would not be possible. For more information, go to www.stjude.org.
Summer Freeman | EurekAlert!
Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences